Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

In Vitro Co-Culture of CLL-B Cells Reveals Long-Term Survival, Proliferation, and Maintenance of Telomere Length

Ceri H Jones, MBBCh, Thet Thet Lin, PhD, Elisabeth Jane Walsby, PhD, Guy E Pratt, MDFRCP FRCPath, Christopher Fegan, Duncan M Baird, PhD, Chris Pepper, PhD

Blood (2016) 128 (22): 350.

https://doi.org/10.1182/blood.V128.22.350.350

Published: 2016

Journal Articles

Genetic Analysis of Distinct Phenotypic Subsets within MM1.S Multiple Myeloma Cell Line Reveals the Pre-Existence of MM.1R-like Glucocorticoid Resistance and a Sub-Clone with an Activating PI3-Kinase Delta Mutation That Is Preferentially Sensitive to the Selective PI3-Kinase Inhibitor, Idelalisib

James W Murray, MBBCh, Christopher Fegan, Chris Pepper, PhD

Blood (2016) 128 (22): 4449.

https://doi.org/10.1182/blood.V128.22.4449.4449

Published: 2016

Journal Articles

Direct Evidence for a Chronic Antigen Driven T Cell Response In CLL Lymph Nodes

Deborah Yallop, MB, BS, BSc.(hons), MRCP, FRCPath, Andrea GS Buggins, PhD, Chris Pepper, PhD, Stephen Devereux, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 915.

https://doi.org/10.1182/blood.V116.21.915.915

Published: 2010

Journal Articles

Cellular Aminopeptidase Inhibition as a Target for the Therapy of AML by the Novel Agent CHR 2797.

Christopher Jenkins, MB, BCh, Ken Mills, PHD, Chris Pepper, PHD, Burnett Alan, MB BCh

Blood (2007) 110 (11): 1608.

https://doi.org/10.1182/blood.V110.11.1608.1608

Published: 2007

Journal Articles

Transcription Factor NF-kB as a Biomarker for Disease Progression and Target for Treatment in Chronic Lymphocytic Leukaemia.

Saman Hewamana, MRCP, MRCPath, Mathew Clement, BSc, Thet Thet Lin, PhD, Chris Jenkins, MRCP, Chris Fegan, FRCP,FRCPath,MD, Clare Rowntree, FRCP,MRCPath,PhD, Paul Brennan, PhD, Chris Pepper, PhD

Blood (2007) 110 (11): 3091.

https://doi.org/10.1182/blood.V110.11.3091.3091

Published: 2007

Journal Articles

CD21 Expression Is Inversely Correlated with the Ability of CLL Cells To Induce Tyrosine Phosphorylation in Response to Anti-IgM.

Chris Pepper, PhD, Suhair Alghazal, MD, Paul Brennan, PhD, Clare Rowntree, MB, PhD, Thet Thet Lin, PhD, Guy Pratt, MD, Chris Fegan, MD

Blood (2006) 108 (11): 2806.

https://doi.org/10.1182/blood.V108.11.2806.2806

Published: 2006

Journal Articles

Integrating Prognostic Markers and Cellular Signaling Identifies More Chronic Lymphocytic Leukemia Patients with Adverse Prognosis.

Paul Brennan, PhD, Suhair Alghazal, MD, Naomi Price Lloyd, PhD, Janet E. Williams, PhD, Jeff D. Griffiths, PhD, Clare Rowntree, MB, PhD, Guy Pratt, MD, Chris Fegan, MD, Chris Pepper, PhD

Blood (2006) 108 (11): 2782.

https://doi.org/10.1182/blood.V108.11.2782.2782

Published: 2006

Journal Articles

Mcl-1 Promoter Insertions as an Independent Prognostic Factor for Treatment Free Survival in Chronic Lymphocytic Leukaemia.

Laura Hooper, MD, Julio Delgado, MD, Jane Starczynski, PhD, Jason Evans, MD, Chris Pepper, PhD, Pamela Greenwell, PhD, Chris Fegan, Md, Guy Pratt, MD

Blood (2006) 108 (11): 4930.

https://doi.org/10.1182/blood.V108.11.4930.4930

Published: 2006

Journal Articles

Constitutive Nuclear p65 NF-kB Expression Predicts for Spontaneous Apoptosis and In Vitro Sensitivity to Fludarabine in CLL Cells.

Saman Hewamana, MB, Clare Rowntree, MB, PhD, Thet Thet Lin, PhD, Chris Pepper, PhD, Paul Brennan, PhD, Chris Fegan, MD

Blood (2006) 108 (11): 4974.

https://doi.org/10.1182/blood.V108.11.4974.4974

Published: 2006

Journal Articles

ZAP-70 Expression Is More Predictive Than V H Gene Mutational Status of BCR-Mediated Tyrosine Phosphorylation, NF-κB Activation and CLL Cell Survival.

Chris Pepper, PhD, Suhair Alghazal, MD, Paul Brennan, PhD, Clare Rowntree, MD, PhD, Guy Pratt, MD, Chris Fegan, MD

Blood (2005) 106 (11): 2942.

https://doi.org/10.1182/blood.V106.11.2942.2942

Published: 2005

Journal Articles

The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.

Chris Pepper, PhD, Chris Fegan, MD, Paul Brennan, PhD, Ken Mills, PhD, Alan K. Burnett, MD

Blood (2005) 106 (11): 2981.

https://doi.org/10.1182/blood.V106.11.2981.2981

Published: 2005

Journal Articles

Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38 + Sub-Clones When Compared with CD38 − Sub-Clones Derived from the Same CLL Patient.

Chris Pepper, PhD, Rachel Ward, BSc, Jane Starczynski, PhD, Clare Rowntree, MD, PhD, Guy Pratt, MD, Ken Mills, PhD, Chris Fegan, MD

Blood (2005) 106 (11): 180.

https://doi.org/10.1182/blood.V106.11.180.180

Published: 2005

NARROW

In Vitro Co-Culture of CLL-B Cells Reveals Long-Term Survival, Proliferation, and Maintenance of Telomere Length

Genetic Analysis of Distinct Phenotypic Subsets within MM1.S Multiple Myeloma Cell Line Reveals the Pre-Existence of MM.1R-like Glucocorticoid Resistance and a Sub-Clone with an Activating PI3-Kinase Delta Mutation That Is Preferentially Sensitive to the Selective PI3-Kinase Inhibitor, Idelalisib

Direct Evidence for a Chronic Antigen Driven T Cell Response In CLL Lymph Nodes

Cellular Aminopeptidase Inhibition as a Target for the Therapy of AML by the Novel Agent CHR 2797.

Transcription Factor NF-kB as a Biomarker for Disease Progression and Target for Treatment in Chronic Lymphocytic Leukaemia.

CD21 Expression Is Inversely Correlated with the Ability of CLL Cells To Induce Tyrosine Phosphorylation in Response to Anti-IgM.

Integrating Prognostic Markers and Cellular Signaling Identifies More Chronic Lymphocytic Leukemia Patients with Adverse Prognosis.

Mcl-1 Promoter Insertions as an Independent Prognostic Factor for Treatment Free Survival in Chronic Lymphocytic Leukaemia.

Constitutive Nuclear p65 NF-kB Expression Predicts for Spontaneous Apoptosis and In Vitro Sensitivity to Fludarabine in CLL Cells.

ZAP-70 Expression Is More Predictive Than V H Gene Mutational Status of BCR-Mediated Tyrosine Phosphorylation, NF-κB Activation and CLL Cell Survival.

The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.

Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38 + Sub-Clones When Compared with CD38 − Sub-Clones Derived from the Same CLL Patient.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only